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8ABSTRACT
Human blood contains a large variety of differentiated cells with a limited 
half-life. New blood cells are continuously provided by self-renewing 
multipotent hematopoietic stem cells (HSC). The capacity of HSCs to 
regenerate the hematopoietic system is utilized in the treatment of 
patients with hematological malignancies. HSCs can be obtained from 
bone marrow (BM) or peripheral blood (PB) after cytokine-induced HSC 
mobilization. In addition, blood from both placenta and umbilical cord 
is also rich in HSCs. Cord blood (CB) can be collected after delivery, 
cryopreserved for the possible future need of an HSC graft for patients 
with no suitable BM donor available.
HSCs can be enriched using an antibody-based recognition of CD34 
glycoprotein on the cell surface. Another glycoprotein, CD133, has also 
been used for identifi cation of primitive cells. The CD133+ cell population 
has been shown to be more homogeneous and contain a higher number 
of potential HSCs than CD34+ cells. CD133 and CD34 molecules are 
often coexpressed, yet the CD133+ and CD34+ cells may have partly 
different roles in hematopoiesis.
Each cell has a glycome typical for that cell type. The glycome of HSCs 
is poorly known. Glycans at the outermost surface of the cell transmit 
various signals between the matrix environment and the surrounding 
cells. A CD34+ cell-specifi c glycoform of CD44, cell adhesion molecule, 
has been shown to have a possible function in HSC homing.
The aim of present studies has been to characterize the global gene 
expression of CB CD133+ and CD34+ cells. Furthermore, the identically 
constituted gene expression profi les of CD133+ and CD34+ cells were 
compared to unravel shared and unique gene expression in CD133+ and 
CD34+ cells. A prioritization algorithm was used to rank the genes best 
separating CD133+ and CD34+ cells from their counterparts, CD133- 
and CD34- cells. Thus, these genes were suggested to play a part in 
the regulation of primitive hematopoietic cells. CD133+ and CD34+ cells 
solely expressed several genes encoding transmembrane proteins that 
could putatively serve to identify HSCs. Moreover, cell type-specifi c gene 
expression was demonstrated in both CD133+ and CD34+ cells. These 
differentially expressed genes were associated with divergent biological 
processes suggesting differences in the transcriptional regulation of 
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9CD133+ and CD34+ cells. Thus, they may represent differences in the 
self-renewal, differentiation or homing properties. Moreover, CD133+ cells 
expressed a higher number of genes associated with HSC maintenance 
and pluripotency indicating the more primitive nature of CD133+ cells. 
Furthermore, the gene expression data bank of CD133+ and CD34+ cells 
may be used to study the pathogenesis of hematological disorders and 
the development of malignancies.
Another aim of these studies was to identify the characteristic 
glycosylation pattern of primitive hematopoietic cells and the genes 
producing the key glycan entities. High mannose type N-glycans were 
the most prevalent glycan type in CD133+ cells. CD133+ cells had 
more biantennary complex type N-glycans than CD133- cells, whereas 
multiantennary complex type N-glycans were fewer in CD133+ cells than 
in CD133- cells. Moreover, the CD133+ cell N-glycans showed enrichment 
of terminal α2,3-sialylation. Combined gene expression and glycan 
profi ling allowed the identifi cation of the key genes regulating the N-
glycosylation characteristic for CD133+ cells. The critical genes were 
similarly expressed in CD34+ cells, suggesting a similar glycosylation 
pattern in CD133+ and CD34+ cells. Knowledge of HSC glycobiology can 
be used to design therapeutic cells with improved cell proliferation or 
homing properties. Improved HSC homing would diminish the number 
of HSCs needed for the therapy of patients, and allow for greater use of 
CB grafts.
ABSTRACT
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Hematopoietic stem cells
HSCs are small cell populations in adult BM. They have enormous capacity 
to self-renew and to generate progenitor cells that can differentiate into 
mature blood cells1. The life span of most white blood cells is from a 
few hours to a couple of days. The most common cell type in blood, red 
blood cells, has an average life expectancy of 120 days. Adult humans 
have tens of billions of red blood cells. Thus, an average of two million 
new red blood cells are required every second. HSCs produce new cells 
to balance the loss of cells each day throughout life.
The mammalian hematopoietic tissue derives from the mesoderm layer 
of the embryo. The HSCs fi rst germinate in the dorsal aorta2. They are 
also produced in the major embryonic vessels, umbilical and vitelline 
arteries2. From the aorta, HSCs migrate to yolk sac, and thereafter to 
liver and BM. In addition, the placenta supports a large stem cell pool 
during development and is suggested to serve as source of pre-HSCs/
HSCs3. The number of HSCs in the placenta and cord veins drops during 
the trimester of the gestation. Yet, blood from the umbilical cord and 
placenta of full-term infant provides a rich source of HSCs. 
BM is the primary location for HSCs in the adult. In addition, small 
amounts of HSCs are in both circulation and in the spleen. Most of the 
HSCs reside in their BM niche in a quiescent, noncycling state. However, 
to sustain hematopoiesis and to maintain the HSC pool, cell divisions 
are required. HSCs have been thought to divide both symmetrically and 
asymmetrically4,5. In symmetric cell division, two identical HSCs are 
formed. Asymmetric cell division leads to the formation of two different 
daughter cells, one that is similar to the mother cell and contains long-
term repopulation capacity, and a daughter cell that has short-term 
repopulation capacity. Long-term HSCs have life-long hematopoietic 
reconstruction capacity. Short-term HSCs have reduced capacity 
to sustain hematopoiesis, but they give rise to lineage committed 
progenitors. According to estimates, only 1/10 000 cells in BM has long-
term repopulation capacity6. Once HSC has been committed to lineage 
differentiation, it no longer has HSC capacity and properties.
The tremendous progeny of HSCs is able to repopulate the marrow. HSC 
transplantation for marrow repopulation after high doses of chemotherapy 
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or total body irradiation is an established procedure for the treatment of 
leukemia. HSC transplantations have also been used in therapy for other 
hematological disorders, immunodefi ciency syndromes, inborn errors of 
metabolism and autoimmune diseases7-9. It has been suggested that 
HSCs have the capacity to differentiate into cells of nonhematopoietic 
tissue as well10-12. Current studies are targeted to fi nd out if HSCs can 
be utilized in the treatment of such diseases as diabetes, Parkinson’s 
disease and spinal cord injury.
Phenotypic characterization
HSCs are morphologically similar to leukocytes. They are found among 
small, rounded cells that have little cytoplasm13. HSCs are mainly 
noncycling. They stain poorly with vital dyes such as rhodamine123, which 
locates the mitochondria of living cell, or Hoechst stains 33342/33258, 
which recognizes DNA of live or fi xed cells. Poorly stainable noncycling 
cells are called Rho/Hoechst 33342low, in contrast to Rho/Hoechst 
33342high which indicate the actively cycling cell population. Thus, Rholow 
cells contain a higher number of HSCs than Rhohigh cells14. Moreover, 
HSCs have high aldehyde dehydrogenase activity that can be used to 
enrich primitive cell populations15.
Leukocytes carry various cluster of differentiation (CD) molecules on 
their cell surface. These have been used as markers to characterize 
cell type, maturity and activity of the cell. There is no single marker to 
identify HSCs, but the presence of the CD34 molecule marks a highly 
enriched HSC population. As a result, CD34-based isolation of HSCs 
is most widely used. CD34 antigen is also carried by hematopoietic 
progenitor cells and cells in the vascular endothelium. Determination 
of the cell type depends on which other CD molecules are present with 
CD34. HSCs are found among a population of CD34+ cells that do not 
express CD38 or other lineage differentiation (Lin) markers such as 
CD2, CD3, CD14, CD16, CD19 CD24, CD56, CD66b and Glycophorin A 
(Figure 1).
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Figure 1. Schematic representation of the hematopoietic lineage differentiation 
markers during hematopoiesis. Modifi ed after Kyoto Encyclopedia of Genes and 
Genomes Pathway Database16.
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However, other markers such as CD90 (Thy-1) and CD117 (c-Kit) are 
carried on HSCs. The expression of CD135 (FLT3) is typical for multi-
potent progenitors17.
Hematopoiesis has been studied mainly in the mouse model. Murine 
HSCs (mHSC) have phenotypic characteristics divergent of human 
HSCs. They are enriched by selecting Lin- cells that carry Sca-1 and 
c-Kit molecules on their cell surface18. Unlike in humans, mHSCs are 
CD34 negative18,19. CD90 is expressed only at low level in mHSCs20. The 
signaling lymphocyte activation molecule family receptors, the presence 
of CD150 molecule and the lack of CD48 molecule, can also be used to 
highly purify mHSCs21. 
A small population of CD34-CD38- cells carrying the CD133 molecule on 
their surface seems to be able to give rise to CD34+ cells in humans22. 
However, in human HSCs, long-term marrow repopulating capacity is 
obtained only after the expression of CD3423. On average, 80% of the 
CD34+ cells carry CD133 on their surface. CD133+ cells are almost all 
CD34 positive as well24. Adult stem cells of non-hematopoietic origin 
have been found to express CD13325-27. Its expression is also typical in 
the embryoid bodies derived from embryonic stem cells28. The CD133 
molecule is present in circulating cells with endothelial differentiation 
capacity, suggesting that the differentiation capacity of CD133+ cells 
might be greater than in CD34+ cells25.
HSC enrichment based on antibody-recognition of cell surface molecules 
is not an ideal method. Antibody binding on HSCs decreases HSC en-
graftment potential, which is an outcome that should be avoided29. HSC 
markers have been present on functionally limited cells30. HSCs can 
have altered cell surface marker expression in in vitro conditions31. Fur-
thermore, both functionally competent HSCs and cells with less capacity 
may have the same phenotype. Many ongoing investigations are aimed 
toward HSC enrichment by methods that take use of such methods as 
density gradient difference between cell types or the divergent selectin 
binding affi nity of HSCs32-35. These methods may exceed up to a three-
fold enrichment of HSCs when compared to a mononuclear cell popula-
tion. However, no methods have been more effi cient in HSC identifi ca-
tion than antibody-based strategies. In the immunomagnetic selection 
of CD34+ or CD133+ cells purities of over 90% can be obtained36. Evalu-
ation of HSC potential requires the study of their functional properties.
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Functional characterization
Functional assays are useful in the measurement of the potential of the 
cell. However, they are complicated to use for cell selection purposes. 
Better understanding of HSC biology may help to develop novel methods 
for fast read-out of HSC potential.
The best model used to measure long-term marrow repopulating capacity 
is provided by severe combined immunodefi ciency mice repopulating 
assay. Of the severe combined immunodefi ciency mice transplanted 
human CD34+CD38- cells, one out of 617 cells is able to engraft37. The 
relatively low capacity of the CD34+CD38- cell population to repopulate 
mouse marrow is affected by the xenoenvironment. Engraftment 
capacity has increased with direct intra-BM transplantation, where one 
out of 44 CD34+CD38- cells has been able to populate the marrow38,39. 
Human CD34+ cells negative for CD133 have not been able to provide 
engraftment in mice model40. Moreover, the number of vacant HSC 
niches in the recipient’s BM regulate the engraftment of transplanted 
HSCs41. 
In vitro assays, such as long-term culture initiating cells or cobble stone 
area forming cells, have also been used to estimate the number of 
long-term HSCs. In these methods, stromal cells are used to support 
HSC development and their colony forming capacity is tested after the 
long-term culture. However, differential kinetics between cells in in vivo 
and in vitro assays indicate that long-term culture conditions may not 
necessarily be able to represent the in vivo long-term repopulation 
capacity of HSCs40.
Colony forming unit assay (CFU) exploits a cell’s ability to produce 
progeny in vitro. The cells possessing multipotent progeny, the highest 
differentiation potential, form granulocyte erythrocyte macrophage 
megakaryocyte colonies. CD133+CD34+ cells’ progeny are mainly 
granulocyte macrophage and granulocyte erythrocyte macrophage 
megakaryocyte colonies40. Thus, CD133+ cells are suggested to be 
more naive than CD133-CD34+ cells, whose progeny also produce some 
unipotent burst-forming erythrocyte and erythrocyte colonies40.
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Cord blood-derived hematopoietic stem cells
CB CD34+ cells have greater proliferation potential and they produce 
signifi cantly more progeny than BM CD34+ cells10,42,43. Thus, the greater 
number of more immature HSCs may be found in CB than in BM ori-
gin44. Moreover, CB HSCs have been shown to be able to differentiate 
into endothelial and cardiomyocyte-like cells45. Unlike BM CD34+ cells, 
the CB CD34+ cell population contains very few B cell lineage commit-
ted CD34+CD19+ progenitors (Figure 1). In addition, late-erythroid 
CD34+CD71highCD64-, late-myeloid CD34+CD33+CD15+ and granulo-
monocytic CD34+CD71+CD64+ progenitors are rarer in CB than BM46. 
On the other hand, early-myeloid CD34+CD33+CD15- and T cell lineage 
committed CD34+CD7+CD3- cells are more abundant in CB than in BM. 
In cell culture, CB-derived CD34+ cells signifi cantly increase their prolif-
eration when exposed to external cytokines and growth factors and are 
easier to culture in vitro than BM CD34+ cells47,48. The environment of 
CB HSCs is different from that of BM HSCs. BM HSCs are attached to the 
osteoblastic cells via the engagement of very late antigen 4 and vascular 
cell adhesion molecule 149,50. The osteoblastic cells secrete growth fac-
tors and cytokines such as interleukin-6, stem cell factor and chemokine 
(C-X-C motif) ligand 12, and provide ligands such as fi bronectin for the 
adhesion of HSC51. CB HSCs are, in contrast, devoid of osteoblastic cells. 
While the placenta is a supportive niche for HSCs in the fetal environ-
ment during midgestation3, the placenta and CB of a full-term infant is 
likely to contain low amounts of growth factors and cytokines. Moreover, 
CB HSCs may be naturally prepared for oxidative stress and survive bet-
ter in the 20% oxygen of most cell culture. The oxygen concentration 
in the CB environment is higher than in BM endosteum, the niche for 
BM HSCs51. The greater success in culturing CB HSCs may also be aug-
mented by the fact that CB HSCs have markedly longer telomeres than 
in BM or PB HSCs’52. This suggests that CB HSCs are able to go through 
more cell duplications than BM HSCs.
Collection and banking
After the fi rst successful CB transplantation in 198853, CB has been 
stored and cryopreserved for potential future use. CB banks have been 
created to increase the availability of CB units. Today, there are tens of 
public CB banks worldwide storing more than 200,000 CB units54,55. In 
addition, an unknown number of CB units have been stored privately. 
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The CB units stored in public banks are available to practically everyone. 
The International NETCORD Foundation provides information regarding 
the CB banks jointly in Europe, the United States, Japan and Australia. 
An online virtual offi ce for real-time searching allows an even faster sur-
vey of available CB grafts and makes their use more effi cient. This espe-
cially enhances the search of grafts for patients with a minority genetic 
background that have only a few suitable stem cell donors available55. 
The accredited CB banks of the Foundation for the Accreditation of Cel-
lular Therapy, such as the Finnish Red Cross Blood Service Cord Blood 
Bank, ensure that minimum requirements for CB quality, handling and 
storage are met56. As a result, accreditation criteria maintain the quality 
of the banked CB.
CB is a byproduct of delivery, it is easy to obtain and ex utero collection 
carries no risk to the donor57. CB collection is similar to PB collection, i.e. 
the cord vein is punctured with a needle and the collection bag is fi lled 
by gravity. Suitable CB donors have no known genetic or transmitted 
disease, have been informed of the situation and have provided written 
consent for the utilization of the donated CB. Further, CB is tested for 
human immunodefi ciency virus, hepatitis C virus, hepatitis B virus, 
human T cell leukemia virus and syphilis. In addition, donor mothers 
have been analyzed for the presence of parvo and cytomegalovirus.
Yet it is not known whether CB cells, cryopreserved for long periods of 
time, are successful in transplantation. The results on mouse marrow 
populating assay and CFU suggest a rather long half-life for stored CB 
units. Thawed CB HSCs have been able to repopulate the marrow in a 
mouse model after 15 years of storage in liquid nitrogen58. The colony 
forming potential of HSCs has been shown to be 97% of that of fresh 
HSCs after 12 years of storage in liquid nitrogen59.
 
Cord blood transplantation
Because fast treatment of the patient may be crucial, CB is a noteworthy 
alternative to transplantation when no suitable related BM donor is 
readily available. CB as readily available and cryopreserved in CB banks 
is faster and easier to obtain than unrelated BM donor graft. To obtain 
BM graft, the donor candidates in the BM donor registry have to fi rst be 
located. Their HLA-typing results are confi rmed, they are informed of 
the collection process and their consent is requested. Moreover, donors 
need to pass a complete physical examination and and need to take 
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additional blood tests to become a suitable BM donor. After all this, the 
date for transplantation can be scheduled. An average of 13.5 or 49 
days are required to obtain CB or BM graft, respectively60. 
CB transplantation has already been performed on approximately 4000 
patients. CB has been used to treat a variety of diseases7-9,55,61. A full list 
of diseases treated by CB transplantation is shown in Table 1. Novel ap-
plications aim to improve the engraftment of CB grafts. Methods such as 
HSC expansion, supplement of CD34+ cells from PB, mesenchymal stem 
cells and platelet microparticles are under investigation62-67. Gene trans-
fer into CB HSCs has been used to improve HSC capacity and their use in 
non-hematopoietic injured tissues. Initial transduced CD34+ cells have 
been successfully used in the treatment of children with severe com-
bined immune defi ciency caused by adenosine deaminase-defi ciency68. 
These patients have been given autologous CB CD34+ cells transduced 
with an adenosine deaminase gene.
Human leukocyte antigen-matched adult donors are not available for 
all the patients. A patient receiving an unrelated CB graft has an equal 
survival prognosis than patients getting a BM graft from an unrelated 
donor69. However, patients receiving a human leukocyte antigen-mis-
matched CB graft from an unrelated donor show less severe graft versus 
host disease than patients treated with an human leukocyte antigen-
mismatched BM or PB graft70-75. It has been suggested that greater 
tolerance of human leukocyte antigen-disparity in CB transplantation is 
due to the immature lymphocytes of newborn76. Also, CB dendritic cells 
are more immature and have diminished functionality when compared 
to PB73. Dendritic cells present antigens to T and B cells and are respon-
sible for initiating and shaping the adaptive immune system.
The main inconvenience of CB transplantation is the limited number 
of cells available in a single CB unit. In CB transplantation, 2x107 cells 
per kilogram is typically considered adequate for transplantation77. The 
number of cells per kilogram is 10 times more in BM transplantation. 
Lower cell dose causes less graft versus host disease, whereas higher 
cell dose has been associated with faster myeloid and platelet engraft-
ment71.
CB grafts have been mostly used in the treatment of pediatric patients. 
However, reduced intensity transplantation or double CB grafts have 
been incorporated to overcome the shortage of cells for the therapy of 
adult patients78-80. Smaller cell doses are suitable for reduced intensity 
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transplantation which may be applied when patients are not strong enough 
to go through standard pre-transplant treatment to destroy disease 
cells81. In the reduced intensity transplantation, the donor immune cells 
are used to fi ght the disease. Moreover, the double CB grafts, when 
compared to the single CB grafts, have shown better engraftment and 
improved graft versus leukemia response in patients82,83.
Despite the lower risk of graft versus host disease with a CB graft, a 
similar graft versus leukemia response has been seen after CB and BM 
transplantations. Immune reconstruction, recovery of early T cells and 
B cells after CB transplantation, is similar to that of BM85,86. However, 
some clinics have observed an increase in treatment-related mortality 
with CB grafts. This has been suggested to be due to slower engraftment 
of the graft, but could also be due to greater human leukocyte antigen-
disparity or lower cell dose of CB grafts used for the treatment. Slower 
engraftment increases the risk of bacterial infections, which seem to be 
slightly more common after CB transplantation87. However, infection-
related mortality is not increased after CB transplantation87.
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Table 1. List of diseases and conditions treated with CB transplantation. 
Adapted from Cord Blood Center84.
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Ex vivo expansion
The ex vivo expansion systems have succeeded in augmenting HSC 
proliferation and increasing the number of progenitor cells with the abil-
ity to generate T lymphocytes and Natural Killer cells88. The challenge 
remaining is the expansion of long-term HSCs. CD34+CD38- cells have 
been expanded in culture, but the marrow repopulating capacity has 
not been increased88. Moreover, expanded and cycling cells have dem-
onstrated increased susceptibility to apoptosis when compared to quies-
cent HSCs89. This could cause the early death of transplanted HSCs and 
impaired initial engraftment.
In the ex vivo expansion, the CB-derived cells are cultured in a 
media supplemented with various growth factors and cytokines such 
as interleukin-1β, -3, -6, -11, stem cell factor, fms-tyrosine kinase 3 
ligand, trombopoietin, granulocyte-macrophage colony stimulating 
factor, erythropoietin and chemokine ligand 3. Alternatively, HSC growth 
has been supported by co-culture with stromal cells or mesenchymal 
stem cells. A variation of this method uses conditioned media containing 
secreted factors from stroma or mesenchymal stem cells. 
The engraftment potential of HSCs is limited mostly to cells in the 
G0 state
90. HSCs induced to proliferate do not reenter the G0 state
91. 
These are the challenges that need to be overcome in order to expand 
HSCs. Fortunately, the quiescent state of the cell is not as critical to the 
engraftment potential of CB HSCs as it is to PB HSCs91.
A better understanding of molecular mechanisms controlling self-
renewal would enhance the ability to expand CB cells. The protein level of 
transcription factor Homeobox B4 (HOXB4) has been shown to positively 
correlate with better in vitro proliferation92. HOXB4 transduced HSCs 
have been shown to maintain mHSC capacity93. Unfortunately, the same 
outcome has not been achieved in humans93. The potential risk with 
transduction-based method and cell culture is that they change HSC 
gene expression and the expression of cell surface molecules94. This 
may have an effect on HSC properties such as homing and therefore on 
the engraftment of the transplanted cells.
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Transcriptome profi ling
In recent years, transcriptome profi ling has been widely used to 
understand the genetic regulation of a particular cell type. Transcriptome 
encompass the global gene expression in a cell at a specifi c time. It 
can proffer valuable information on the signifi cant biological processes 
behind the maintenance of the functionality of the cell. Transcriptome 
profi ling is used to reveal the key genes involved in HSC self-renewal 
versus differentiation decisions.
The technology for the study of transcriptome is not dependent on 
any prior knowledge of the genes expressed in the cells of the study. 
However, challenges remain in regards to the administration and in-
terpretation of the enormous data provided by transcriptome profi ling. 
Transcriptomics provides fundaments for more defi nitively designed 
studies and guidance to select the genes for functional studies. It 
should be kept in mind that the small change in the expression level 
of a gene may relate to a great difference in the total amount of the 
corresponding protein present in the cell. The presence of a molecule 
in a cell depends on the translation features of the mRNA sequence and 
the amount of antisense sequences degrading the corresponding sense 
sequences95,96. Results from the transcriptome and proteome analysis 
of a similar cell type can not usually be fully matched partly due to 
the heterogeneity or instability of the proteins97. Technical limitations 
may also explain some of the divergences found in trancriptome and 
proteome level98.
Methods for transcriptome profi ling
Gene expression profi ling of 45 Arabidopsis thaliana genes was reported 
in 1995 as the fi rst microarray-based experiment99. Today there are 
many different kinds of microarray chips used, some of which are the 
laboratories own cDNA arrays and others which are commercially pro-
duced microarrays. The basic idea behind these is the same (Figure 2). 
Preanalysis and normalization of the data prior to the analysis of the 
results is one noticeable part of the data interpretation.
Microarray analysis is still the most widely employed technology for 
transcriptome profi ling, but serial analysis of gene expression (SAGE) 
(Figure 3) and subtractive hybridization (Figure 4) have also been com-
monly used. Microarray is designed for the study of differential gene 
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Figure 2. Schematic representation of microarray technology. Total RNA from the 
cell is isolated and converted into cDNA. cDNA is labeled and hybridized to an array 
containing oligonucleotide probes. After hybridization, the level of fl uorescence of the 
attached sequences on the chip is measured with a laser scanner, and microarray 
analysis methods are used to calculate the abundance of each represented RNA. 
Adapted from Affymetrix GeneChip Expression Analysis Technical Manual100.
expression. The subtractive hybridization reveals solely the differen-
tially expressed genes. On the other hand, SAGE technology is effi cient 
in detection of the copy number of the transcripts expressed.
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Figure 3. The overview of SAGE technology. RNA from the cells is converted into cDNA 
molecules in the presence of oligo(dT) magnetic beads. Immobilized cDNA is cleaved with 
an anchoring enzyme (usually NlaIII) and tagged (usually with BsmFI) to form SAGE 
tags. Tags are combined to di-tags, amplifi ed and linked to concatamers of several SAGE 
tags. Concatamers are cloned in bacteria and then sequenced to reveal the identity and 
abundance of unique sequences. Modifi ed after (Broxmeyer HE 2004) with data from 
Serial Analysis of Gene Expression101,102.
Several other methodologies such as differential display analysis, 
representational difference analysis, massive parallel signature 
sequencing and analysis of expressed sequence tags can also be utilized. 
The advantages and disadvantages of the three most commonly used 
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Figure 4. The general concept of subtractive hybridization. RNA or cDNA from the cells 
of interest is hybridized to single-stranded cDNA-containing paramagnetic beads from 
control cells. Hybrids and excess driver cDNA are removed using a magnet. The remaining 
fragments present the RNA expressed specifi cally in the cells of interest. Modifi ed from 
(Lönneborg et al. 1995)103.
technologies; microarray analysis, SAGE and subtractive hybridization 
are summarized in Table 2. The high costs of using several high 
throughput methods often limit parallel use of these technologies by a 
single laboratory. Instead, quantitative real-time reverse transcriptase-
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polymerase chain reaction (qRT-PCR) is often used to verify global gene 
expression profi ling results. Usually this means that expressions of a 
selected set of genes are reanalyzed.
Table 2. Comparison of three different methods for gene expression 
analysis.
It has been shown that results from qRT-PCR, microarray and SAGE are 
usually correlated, especially when the gene is expressed on the high or 
medium level104. As a sequence-based technology, the sensitivity of qRT-
PCR and SAGE analysis is higher than the sensitivity of hybridization-
based microarray analysis. Both qRT-PCR and SAGE are able to detect 
gene expression at a very low level. The level of differential gene 
expression is often detected lower in microarray analysis than in qRT-
PCR105.
Gene expression profi ling of murine hematopoietic stem 
cells
Previously, particular with the earliest studies, the focus was on 
discovering transcriptional regulation of mHSCs. Despite the differences 
in the genes related to hematopoiesis in mice and humans, murine gene 
expression profi ling has proven to be valuable in understanding HSC 
biology. Genetic programming in stem cells has been underlined in the 
comparison of the transcriptional expression in HSCs, progenitors and 
mature hematopoietic cells.
27REVIEW OF THE LITERATURE
The fi rst large scale analysis of HSCs identifi ed over 2000 genes 
differentially expressed in fetal mHSCs (AA4.1+Sca+c-Kit+Lin-/low) and 
mature leukocytes (AA4.1-)106. The primitive cells showed enriched 
expression of genes associated with cell signalling, RNA synthesis, 
metabolism, protein synthesis, cell division, cell structure, and cell 
defence. The majority (53%) of the expressed transcripts were not 
previously known. Gene expression associated with cell signalling has 
been particularly prevalent in long-term HSC populations, whereas an 
increase in cell cycle initiation, DNA repair and protein synthesis has 
been shown to be characteristic of short-term HSCs. Genes typical to 
lineage committed progenitors are expressed in low levels in short-term 
mHSCs107.
In the study of gene expression in HSCs and various lineage committed 
progenitors, 43% of the differentially expressed genes were shown to 
be specifi c to the HSC population108. Gene expression profi les of fetal 
and adult mHSCs have been shown to have 70% overlap109. Fetal HSCs 
express a few embryonic stem cell-related genes such as Dnmt3b and 
microH2A1.2 that have not been found to be prevalent in adult BM HSCs. 
It has also been shown that fetal HSCs are in an active state of cell cycle 
more often than adult HSCs110,111.
HSCs and neural stem cells have shown common gene expression not 
present in mature hematopoietic and neuronal cells108. However, highly 
HSC enriched cells have shown more similar gene expression patterns 
with mature hematopoietic cells than with stem cells from neural or 
embryonic origin112. Different stem cell types possess more similarities 
in the representative biological processes than on the level of individual 
genes113. Genes associated with chromatin remodeling have been 
upregulated in various stem cell populations. It has been suggested 
that this process regulate the self-renewal and differentiation potential 
of stem cells114. Of the genes common to all stem cell populations, 
only 4 transcripts uridine phosphorylase, suppressor of Lec15 and two 
expressed sequence tags have been identifi ed. This suggests that only 
a few genes have restricted expression in stem cells112.
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Gene expression profi les of human hematopoietic stem cells
The differential gene expression between BM, PB and CB-derived CD34+ 
cells may be related to the possible differing roles of CD34+ cells in 
different environments10,109,115. The HSC mobilization actuate the 
gene expression resulting in partly divergent gene expression in BM 
or granulocyte colony-stimulating factor mobilized CD34+ cells from 
humans116. Cell cycle promoting genes are more common in BM CD34+ 
cells than mobilized PB CD34+ cells. The number of genes encoding 
transcription factors or gene products associated with apoptosis is 
abundant in mobilized cells when compared to BM CD34+ cells116. The 
gene expression in CB and BM CD34+ cells is more similar than gene 
expression in mobilized PB CD34+ cells10,115. BM CD34+ cells have shown 
enriched expression of genes associated with support of myeloid lineage 
development and inhibition of apoptosis. Cell adhesion and mobilization-
associated genes such as CXCR4, which is important in the homing and 
engraftment of CD34+ cells, are underexpressed in CB CD34+ cells when 
compared to BM CD34+ cells. 
Typically, a high amount of expressed genes is common to HSCs. This 
may be due to their relatively open or transcription permissive chromatin 
structure117,118. CB CD34+ cells have the highest number of overexpressed 
genes when CB, BM and PB CD34+ cells are compared10,115. The number 
of overexpressed genes is higher in BM CD34+ cells than in PB CD34+ cells. 
The greater number of active genes suggests broader transcriptional 
options for HSCs. Many genes expressed by HSCs have been located in 
the pericentric heterochromatin, unlike the genes related to activation 
in mature lymphocytes located in centromeric heterochromatin118. This 
suggests at least a partly different pathway for the activation of genes 
in HSC and mature lymphocytes. Its possible role is to provide fast 
recruiting cells to generate the type of blood cells needed.
Low levels of embryonic stem cell marker gene Oct4 have been de-
tected in CB CD133+ cells119. Other pluripotent markers such as Sox1, 
Sox2, FGF4 of Rex1 are also expressed in CB CD133+ cells119. These 
fi ndings suggest that CD133+ cells, especially from CB, may have the 
potential to differentiate into nonhematopoietic tissue types. Moreover, 
the slowly dividing CB CD34+CD38- cells have been shown to express 
several genes differently when compared to fast dividing CD34+CD38- 
cells120. These slowly dividing, more primitive, hematopoietic cells were 
shown to express CD133 abundantly.
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Glycosylation
Glycosylation is specifi c to each cell type. It involves common posttrans-
lational modifi cations that take place on the nascent protein. There are 
two kinds of glycosylation; N-glycosylation and O-glycosylation. Nearly all 
proteins traveling through endoplasmic reticulum become N-glycosylated. 
Glycosylated proteins mainly function in the extracellular compartments 
and in the secretory pathway. Due to their location on the cell surface, 
they serve a role as providers of information transfer in cell recognition 
and in interactions with other cells or in the extracellular matrix.
Revealing glycosylation features characteristic of HSCs broadens the 
knowledge of HSC biology. Two molecules may have identical amino acid 
composition, but differ due to differential glycosylation. Diverse glyco-
forms of Thy-1, a stem cell marker, have been found in the thymus and 
brain121. Moreover, individual glycosylation leads to the formation of blood 
groups such as ABO(H), Secretor, P and Lewis on erythrocytes122. Changes 
in glycosylation are involved in cell differentiation, embryogenesis and 
tissue morphogenesis.
N-glycans and N-glycan synthesis
N-glycans support protein folding, stability and oligomerization, and par-
ticipate in traffi cking, recognition of receptor binding sites and protein 
localization. N-glycans are vital for organisms from yeast to human, and 
most of the known glycosylation disorders are caused by defective N-
glycosylation123,124. The defects have been most dramatic in cells going 
through rapid alterations, such as leukocytes. For example, the inhibition 
of N-glycan backbone trimming mannosidases cause a blockage in B cell 
differentiation125 (Figure 5). In addition to N-glycan, other glycan types 
including O-glycans, glycosphingolipids, glycosaminoglycans and glyco-
phospholipid anchors are common126. Due to the technical challenges 
of studying the structure of these other gycan types, they are less well 
known.
In the biosynthetic pathway of N-glycosylation, the preformed glycan is 
transferred to the amino acid asparagine (N) glycosylation site on the 
nascent protein in endoplasmic reticulum (Figure 6). N-glycans can be 
grouped into three classes; high mannose, hybrid and complex type 
structures, depending on the amount and type of glycan modifi cations 
they have gone through127 (Figure 6).
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Figure 5. Schematic representation of N-glycans. N-glycans consist of distinct regions 
of N-glycan core, backbone and terminal epitopes that are synthesized by different 
glycosyltransferase and glycosidase families. Monosaccharide symbols:      = N-acetyl-D-
glucosamine;    = D-mannose;    = D-galactose;    = L-fucose;    = N-acetylneuraminic 
acid.
High mannose N-glycans represent the unprocessed glycan structures 
with a maximum of 9 D-mannoses attached to the N-glycan core. The 
hybrid type or intermediately processed glycans possess characteristics 
of both high mannose and complex type N-glycans. Complex type 
glycans are so-called fully processed N-glycans and occur as bi-, tri-, 
tetra- or pentaantennary structures.
The α-mannosidase 1 enzymes encoded by MAN1 genes and β-N-acetyl
glucosaminyltransferase 1 encoded by MGAT1 promotes the conversion 
of high mannose N-glycans into more processed glycan types (Figure 6). 
MAN1 gene products remove the terminal α-mannose residues, while β-
N-acetylglucosaminyltransferase 1 transfer an N-acetyl-D-glucosamine 
residue to form the fi rst branch towards processing more developed 
N-glycans. The synthesis of hybrid and complex type N-glycans is 
developmentally essential128.
MAN2 genes encode α-mannosidase 2 enzymes, which trim the hybrid 
type N-glycans prior to the action of MGAT2 coded β-N-acetylglucosami-
nyltransferase 2. Further, β-N-acetylglucosaminyltransferase 2 forms 
the complex type N-glycans. Complex type N-glycans have also been 
found in MAN2-defi cient mice despite the absence of family 2 α-man-
nosidases129. This suggests that there are other enzymes, possibly other 
α-mannosidases, involved in the demannosylation of hybrid type N-gly-
cans. Accumulation of hybrid type N-glycans and the lack of complex N-
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glycans in organisms may affect cell signaling. A mutation in the human 
ortholog of the MGAT2 gene has been associated with a rare human 
disease known as congenital disorders of glycosylation type IIa130. This 
disease affects disfunction of multiple physiological systems.
The tri-mannosyl core on N-glycans of both hybrid and complex types 
can be modifi ed by MGAT3 encoded β-N-acetylglucosaminyltransferase 
3, which adds the so called bisecting N-acetylglucosamine. Two other 
branching moieties, the tri- and tetra-antennary structures, are gener-
Figure 6. N-glycan synthesis. The attachment of N-glycan precursor to the gly-
cosylation site asparagine (N) of a nascent protein initiates the synthesis. Further, 
the three glucose and one mannose residues are enzymatically removed from the 
N-glycan. The processing of N-glycan into the hybrid type starts by the removal of 
the mannose monosaccharides by family 1 mannosidases and adding one N-acetyl-
D-glucosamine by β-N-acetylglucosaminyltransferase 1. The rest of the removable 
mannoses are docked by mannosidase 2 family members. Different glycosyltrans-
ferases, modifying the glycan backbone and terminal epitopes, form the vast variety 
of N-glycans by differentially adding N-acetyl-D-glucosamine, D-galactose, L-fucose 
and N-acetylneuraminic acid residues. Monosaccharide symbols:    = glucose;    = 
N-acetyl-D-glucosamine;    = D-mannose;    = D-galactose;    = L-fucose;    = 
N-acetylneuraminic acid. Glycosidic linkages are indicated by lines connecting the 
monosaccharides.
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ated by MGAT4a, MGAT4b and MGAT5 encoded β-N-acetylglucosami-
nyltransferases. Insuffi cient expression of MGAT4a has been shown to 
cause failure in pancreatic beta cells leading to type 2 diabetes131. In 
some cases, β-N-acetylglucosaminyltransferase 5 forms another branch 
in the α1,3-linked core mannose. MGAT5 does not seem to be essential 
for survival132. On the other hand, enhanced MGAT5 expression has 
been demonstrated to support tumor growth and metastasis133.
The variability of N-glycans is increased with terminal epitopes modifi ed 
by β1,4-, β1,3-galactosyltransferases, α2,3-, α2,6-sialyltransferases 
and α1,2-, α3/4-, α1,6-fucosyltransferases (Figure 5). Mutations in the 
terminal epitopes are not usually crucial for survival, but they often affect 
cells in the hematopoietic system. Mice with mutations in the B4GALT1 
gene have reduced neutrophil traffi cking in the infl amed tissues134. 
In humans, the mutation in B4GALT1 cause congenital disorder of 
glycosylation type IId disease with severe neuronal disease and blood 
clotting defects135,136. The role of the 4 other β1,4-galactosyltransferases 
in N-glycans synthesis is poorly known. However, it has been suggested 
that these β1,4-galactosyltransferases have overlapping functions. 
Immunodefi ciency and attenuated B cell formation has been observed in 
ST6Gal1-knockout mice137. ST3Gal4 is involved in the biosynthesis of si-
alyl-Lewisx and sialyl-Lewisa antigens, both known as selectin ligands138. 
ST3Gal4-defi ciency causes infl ammation response defi cit, formation of 
defi cient platelets and defects in blood coagulation139. The role of ST-
3Gal6, the fourth α2,3-sialyltransferase in the N-glycan synthesis is still 
obscure140.
Fucosyltransferases do not seem to be essential in mice141-144. However, 
FUT genes have an important role in hematopoiesis and the immune 
response. FUT4-null mice have partial neutrophil adhesion defi cit and 
selectin ligand defect similar to the FUT7-knockout144,145. The selectin 
ligand activity is completely lost in FUT4 and FUT7 knockout mice144, 
suggesting that the gene products are pivotal glycosyltransferases re-
sponsible for the synthesis of active selectin ligands. In humans, the 
mutation in the FUT7 gene results in modest reductions of leukocyte 
selectin ligand activity146.
Considerable glycosylation differences are prevalent between organisms. 
All other mammals except the humans, apes and Old World monkeys, 
have functional α1,3-galactosyltransferase147. In humans, the Gal-
α1,3-Gal glycoconjucates synthesized by α1,3-Galactosyltransferase 
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are antigenic and induce serum anti-Gal antibodies148. Moreover, the 
defect in N-glycolylneuraminic acid synthesis is specifi c to humans149. 
The glycosylation differences between organisms need to be taken into 
account when defi ning the components of a cell culture media for stem 
cells to be transplanted into humans150,151.
Glycosylation in hematopoiesis
One of the most dramatic alterations of glycosylation occurs at the time of 
postnatal development, where fetal erythrocyte i type polylactosamine 
changes into branched I type polylactosamine152. Thus, glycans can 
be used as biomarkers for cellular maturity. Moreover, typical glyco-
sylation features of hematopoietic lineages separate the different cell 
types. Lymphoid cells have a large amount of N-glycan α2,6-sialylation, 
whereas sialyl-LewisX antigens are enriched in myeloid cells153,154. In 
these cells, a localized increase in α2,6-sialylation of CD11b/CD18 
molecules has been seen during myeloid cell maturation and liberation 
from BM155.
 
Glycosylation of HSCs is still poorly known. α2,6-sialylation is also 
dominant in CD34+ cell N-glycans156. α2,6-sialylation has been 
increased in granulocyte growth stimulating factor mobilized CD34+ 
cells when compared to naturally circulating CD34+ cells157. It has been 
suggested that sialylation events modify the adhesion between HSCs 
and osteoblasts158. 
Effect of glycosylation on homing
Glycosylation plays an important role in the adhesion and homing of 
HSCs and leukocytes occurring in a selectin-dependent manner159. Leu-
kocyte rolling on endothelial cells is supported by the interaction between 
the lymph node homing receptor L-selectin and its ligands. Leukocytes 
express the P-selectin glycoprotein ligand 1 which is able to bind to L-, 
P- and E-selectins160,161. The selectin binding of P-selectin glycoprotein 
ligand 1 is dependent on O-glycosylation162. 
CB CD34+ cells have impaired α1,3-fucosylation not seen in BM HSCs163. 
CB CD34+ cells express a form of P-selectin glycoprotein ligand 1 that 
does not bind to P-selectin163. Enforced α1,3-fucosylation of CB CD34+ 
cells improved the binding to P-selectin possibly in a P-selectin glycopro-
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tein ligand 1 -dependent manner164. α1,3-fucosylation is important for 
the synthesis of the selectin ligand glycan structure sialyl-Lewisx144.
A selectin ligand, CD44, has a specifi c role in CD34+ cells binding to both 
L and E-selectin165,166. A CD34+ cell specifi c glycoform of CD44 contains 
N-glycosylation, which is crucial to its function165,167. CD44 has been 
suggested to play a major role in CD34+ cell adhesion and movement 
along endothelium and leukocytes168.
In human leukemia CD34+ KG1a cells, the CD34+ cell-specifi c CD44 has 
been shown to have a 5-fold higher affi nity to selectin binding than P-se-
lectin glycoprotein ligand 1165,166,168. Both P-selectin glycoprotein ligand 
1 and CD44 may participate in the homing of HSCs and the dysfunction-
al P-selectin glycoprotein ligand 1 in CB-derived cells may conduce to 
reduced homing capacity of CB HSCs164,165,168. The enforced fucosylation 
of the glycans of CB CD34+ cells have shown contrasting results in their 
ability to improve their homing163,164.
The modifi cation of HSCs by glycan remodelling may provide new tools 
for HSC therapeutics. Engineering of cells through glycan modifi cations 
could be used to enhance HSC homing capacity. This would provide a 
greater use for CB HSCs, as a lower number of cells might be suffi cient 
for successful engraftment.
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AIMS OF THE STUDY
The aims of this study were
1. To characterize the global gene expression and glycome of 
human hematopoietic CD133+ and CD34+ cell populations from 
CB (studies I-III)
2. To reveal the differential gene expression in CD133+ and CD34+ 
cells and to relate the fi ndings to the characteristic biological 
processes of these cells (study II)
3. To identify the genes responsible for cell type-specifi c N-
glycosylation in CD133+ and CD34+ cells (study III)
4. To fi nd novel molecular markers specifi c to HSCs (study II)
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MATERIALS AND METHODS
Ethics
This study was approved by the ethical board of the Finnish Red Cross 
Blood Service and Helsinki University Hospital. The CB donors were 
informed and written consent was obtained. Only CB units unsuitable for 
therapeutic use were studied. A small total volume or the low number of 
total cells were the most common reasons for discharging CB units.
Cells
CB units were collected at the Helsinki Maternity Hospital and the 
Department of Obstetrics and Gynaecology at Helsinki University 
Hospital. The collections were performed during 2004-2007. In all the 
studies, fresh CB units were used.
In study I, CD133+ cells were selected from the 4 CB unit and CD133- 
cells were collected for control purposes. CD133+ data were compared 
to CD133- data from the same CB unit in the microarray analysis. The 
differential gene expression between CD133+ and CD133- cells was to 
be the same in all replicates. The fold-change cutoff value was set to 3. 
To verify the information obtained from the microarray data, selected 
genes were subjected to qRT-PCR analysis using pools of three samples 
in each. Analysis was performed on two biological replicates. In addition, 
CD133+ and CD133- cells were used to evaluate the purity of the cell 
fractions. The CFU assay was performed for CB CD133+, CD133- and 
mononuclear cells in duplicate.
In study II, CD34+ cells were selected from the 3 CB unit and CD34- 
cells were collected for control purposes. Similarly to study I, CD34+ 
data were compared to CD34- data from the same CB unit and the 
results verifi ed using qRT-PCR analysis. Moreover, the assessment of 
the purity of the cell fractions and the CFU assay were performed for 
CD34+ and CD34- cells as in study I. Further, similarly constructed 
CD133+ and CD34+ gene expression profi les were compared to reveal 
the specifi c expression patterns and differences of CD133+ and CD34+ 
cells. In addition, gene expression data of CD133+ and CD34+ cells 
were directly compared to the gene expression data of PB mononuclear 
cells. Thus, the PB mononuclear cell sample was provided as a common 
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benchmark to control the differential gene expression in CD133+ and 
CD34+ cells. 
In addition, the gene expression profi le results suggested several 
putative membrane proteins that could serve as an HSC marker in the 
isolation of HSCs. For the analysis of the presence of novel HSC marker 
molecules, selectively monoclonal antibody-labeled CB mononuclear 
cells were the subject of the fl ow cytometric analysis.
In study III, CD133+ and CD133- cell N-glycans were isolated for mass 
spectrometric analysis. During the preparation process, ultrapure bovine 
serum albumin was used to avoid oligosaccharide contamination. To 
demonstrate the quantitative differences between N-glycosylation of 
CD133+ and CD133- cells, CD133+ and CD133- cell N-glycan profi les 
were compared to each other. In addition, CB CD133+ and CD8+ T cell 
N-glycan profi les were compared to each other. The CD8+ T cell N-glycan 
profi le served as an independent, immunoganetically selected mature 
hematopoietic cell control.
The mononuclear cells were analyzed in nuclear magnetic resonance 
(NMR) analysis to obtain detailed data about most abundant N-glycan 
structures. In addition, N-glycan fractions of CD133+ and CD133- cells 
were digested with specifi c exoglycosidase enzymes to characterize the 
terminal epitopes on CD133+ and CD133- cell N-glycans. Further, the 
glycan profi le and glycosylation-related gene expression were compared 
to unravel the transcriptional regulation of the glycosylation features 
characteristic of CD133+ cells. Also, the glycosylation-related gene 
expression of CD34+ cells was observed. The glycan determinants on 
the cell surface of mononuclear and CD34+ cells were demonstrated by 
a lectin binding assay. For this, Glycophorin A-depleted CB mononuclear 
cells from 3 CB units were used.
Methods
Methods used in the following studies (I-III) are described in detail in 
the original publications and are listed in Table 3.
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Table 3. The methods used in studies I-III36,100,169-180.
39MATERIALS AND METHODS
Gene expression reanalysis
The improved knowledge on gene and transcript sequences, as well as 
genome assembly, reveal a great number of previously defi ned probe 
sets in Affymetrix microarray GeneChips that are not applicable in the 
detection of the gene. The unreliable representative gene identifi er has 
been assigned for approximately 18% of the probe sets in the Affymetrix 
Human Genome U133 Plus 2.0 chip181. Moreover, about 12% of the probe 
sets contain probes that may hybridize to transcripts of more than one 
gene or to a non-coding sequence, while some probes no longer match 
any sequence in the current databases. Thus, reanalysis of all the gene 
expression data was performed to access more accurate annotation of 
the differentially expressed genes.
Raw data was normalized using the GC Robust Multi-array Average 
background adjustment for intensities, quantile normalization, and 
median-polish summarization182. Biostatistic tools were used in R 
software. The probes of each Affymetrix probe set, directed toward 
identifi cation of a transcript, were redesigned to sets of probes 
using GeneChip library fi les (http://brainarray.mbni.med.umich.edu/
CustomCDF). The probe sets of these library fi les were chosen to match 
a more recently updated Unigene cluster representing certain genes 
(http://arrayanalysis.mbni.med.umich.edu/ps/)181. To obtain CD133+ 
and CD34+ cell gene expression profi les, CD133+/CD34+ cells were 
compared to CD133-/CD34- cells. From the CD133+ and CD34+ profi les, 
500 genes with the most differential expression pattern were selected 
according to their median fold change. That is, the ratio of the median 
gene expression level in CD133+/CD133- cells or CD34+/CD34- cells was 
calculated and transformed to an absolute value of log2. Differentially 
expressed genes could be overexpressed or underexpressed in CD133+/
CD34+ cells when compared to CD133-/CD34- cells. The statistical 
signifi cance of the differential expression was performed using a T-test. 
The differentially expressed genes with a q-value>0.05 refl ected the 
probability of a false positive result and were discharged. To directly 
compare differences in CD133+ and CD34+ cells, a pairwise analysis 
utilizing GeneSifter software was employed183. The signifi cant change 
in the expression between CD133+ and CD34+ cells was validated using 
Student’s T-test and a p-value that was ≥0.05.
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Annotation
Due to the ongoing changes and revisions in the annotations of Affyme-
trix probe sets, the differentially expressed genes in studies I and II were 
reannotated using the GeneAnnot Microarray Gene Annotation software 
(Weizmann Institute of Science, http://bioinfo2.weizmann.ac.il/genean-
not/)184,185. The Database for Annotation, Visualization and Integrated 
Discovery tools were employed to obtain molecular functions, biological 
processes, and cellular components for the transcripts common in the 
CD133+ and CD34+ expression profi les in the original and reanalyzed 
data186. The molecular interactions for the protein products were as-
sessed through GeneSifter software, which uses Kyoto Encyclopedia of 
Genes and Genomes Pathway database16.
41RESULTS AND DISCUSSION
RESULTS AND DISCUSSION
CD133+ and CD34+ cells have similar gene 
expression (studies I and II)
The comparison of CD133+ and CD133- data sets resulted in 690 tran-
scripts that were differentially expressed at least three-fold in all the 
samples. Of these, 393 transcripts were upregulated and 297 were down-
regulated in CD133+ cells. Similarly, CD34+ data sets were compared 
to CD34- data sets and 620 differentially expressed transcripts with at 
least a three-fold difference were found. In CD34+ cells, 169 transcripts 
were overexpressed and 451 transcripts underexpressed. The inte-
grated sets of differential gene expression between CD133+ and CD133- 
cells, and CD34+ and CD34- cells, showed that 85% of the transcripts 
overexpressed in both CD133+ and CD34+ cells and 36% of the tran-
scripts underexpressed in both CD133+ and CD34+ cells were the same. 
Transcripts found in both CD133+ and CD34+ cells showed the highest 
overexpression when compared to CD133-/CD34- cells. Both cell types 
expressed many genes previously identifi ed to be present in HSCs (such 
as KIT, LAPTM4B, MEIS1, RBPMS, HLF, BAALC and C17)109,115,120,187-190. 
Also, many genes supporting the undifferentiated state of HSC (such as 
GATA2 and N-MYC and HOXA9)106,191,192. These genes were expressed 
at a very similar expression level across the CD133+ and CD34+ cell 
replicates indicating an important role for these genes in the regulation 
of CD133+ and CD34+ cells. Both cell types expressed a high number 
of transcripts. In addition, these transcripts were arranged similarly in 
SOM analysis suggesting similar regulation for the common genes in 
CD133+ and CD34+ cells. In the CD133+ profi le, the number of over-
expressed transcripts was higher than in the CD34+ profi le. This could 
explain the additional cluster of overexpressed transcripts illustrated in 
U-matrix of CD133+ data.
CD133+ and CD34+ cells expressed 85 transcripts that were not pres-
ent in CD133- or CD34- cells. These transcripts were either downregu-
lated or absent in PB mononuclear cells. The 85 common transcripts 
represented 80 genes. The encoded molecules are involved in cell pro-
liferation, metabolism and localization. Of these, the expression of 44 
genes in HSCs has been confi rmed in other studies109,115,120,188,193. The 
transmembrane protein encoding genes FLT3 (CD135), ALCAM (CD166) 
and DSG2 were expressed in CD133+ and CD34+ cells only. Moreover, 
expression of SV2A was found in CD133+ cells, but not in CD34+ cells. 
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Novel molecular markers for HSCs could not be 
found (study II)
To determine whether transmembrane protein encoding genes expressed 
solely in CD133+ and CD34+ cells could provide novel molecular markers 
for HSCs, the presence of the protein products on the cell surface were 
observed. Total leukocyte population was labeled with specifi c antibodies 
binding to CD135, CD166, DSG2 or SV2A. In addition, anti-CD34 or 
anti-CD133 antibody labeling was used. Coexpression of CD135 and 
CD34/CD133 molecules was demonstrated (Figure 7). Moreover, CD166 
was expressed on some of the CD133+/CD34+ cells (Figure 6). CD135 
was also present on 11% of the leukocytes and CD166 was carried by 
20% of the leukocytes. Thus, neither CD135 nor CD166 alone can be 
used for selective purifi cation of HSCs.
SV2A or DSG2 molecules could not be found on leukocytes, including 
CD133+/CD34+ cells. It is possible that the antibodies against SV2A and 
DSG2 molecules do not posses adequate specifi city. Therefore, no single 
molecular marker to identify HSCs could be found using microarray 
analysis. In addition, known embryonic stem cell markers SSEA3, SSEA4, 
TRA-1-60 and TRA-1-81 were searched for on the leukocytes (data not 
shown). No hematopoietic cell populations carrying these markers could 
be demonstrated.
Figure 7. Presence of CD135 and CD166 molecules on CD34+ and mononuclear 
cells.
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Differential gene expression between CD133+ and 
CD34+ cells suggests that CD133+ cells are more 
primitive (studies I and II)
Despite the highly similar gene expression in CD133+ and CD34+ 
cells, unique gene expression patterns related to divergent biological 
processes were distinguished in CD133+ and CD34+ cells. The number 
of overexpressed transcripts in CD133+ cells, when compared to CD133- 
cells, was higher than in CD34+ cells when they were compared to CD34- 
cells. 
In the study I, a set of 257 transcripts were identifi ed expressed in 
CD133+ cells, but not in CD133- cells. Of these, 125 genes were also 
expressed in CD34+ cells. However, the 172 transcripts overexpressed 
solely in CD133+ cells (when compared to CD133- cells) showed 
signifi cant association with regulation of chromatin structure, cell cycle 
and DNA metabolism. CD133+ cells expressed SMARCA1, SMARCA2 
and SMARCA4. SMARCA genes are related to chromatin remodeling 
pathway194,195. Only SMARCA1 expression was detected in CD34+ cells. 
The high number of expressed transcripts is typical for HSCs that have 
been suggested to have permissive or more open chromatin structure.
Embryonic stem cell-related transcripts including DNMT3A, DNMT3B and 
DPPA4 were shown only in CD133+ cells. The expression of transcripts 
related to pluripotency suggests a more primitive nature for CD133+ 
cells. The embryonic-type gene expression may also be due to the CB 
origin of the cells. The expression of MPDZ, encoding a protein associated 
with tight junctions and maintenance of cell polarity, suggests that some 
of the CD133+ cells may be going through asymmetric cell division.
The products of the expressed transcripts in CD34+ cells were related to 
regulation of development, response to stimulus and DNA metabolism. 
These biological processes were also typical of CD133+ cells. On the 
other hand, CD34+ cells expressed transcripts encoding markers for 
lineage committed cells. 
Several studies have shown transcriptional as well as functional differences 
between CD34+ cells from CB, BM and PB115,196-198. These studies have 
suggested a more primitive nature for CB CD34+ cells. Moreover, 
differential gene expression has been found between CB CD133+ and 
PB CD133+ cells193. This study demonstrated divergent gene expression 
between CB CD133+ and CD34+ cells. The gene expression profi les of 
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CD133+ and CD34+ cells were identically constructed. The samples 
were prepared in the same laboratory, hybridized at the same time and 
analyzed using equal parameters. Therefore, many nonbiological error 
sources for differential gene expression between the two cell populations 
were avoided. The CD133+ and CD34+ gene expression profi les of the 
present study were also compared to CD133+ cell gene expression 
profi le in another study193. CD133+ gene expression profi les were more 
similar to each other than with CD34+ cell gene expression profi le of 
the present study. This confi rms that the different transcriptional 
expression in CD133+ and CD34+ cells is due to differences in these two 
cell populations. 
The differentially expressed transcripts between CD133+ and CD34+ cells 
were related to divergent biological processes, suggesting different role 
for these cells in hematopoiesis. The divergences between CD133+ and 
CD34+ cell populations may be more obvious in those cells from BM or 
PB. It may also be that the divergences between CD133+ and CD34+ cells 
refl ect specifi c primitiveness of CB CD133+ cells. 
CD133+ and CD34+ cells demonstrate similar total 
colony forming potential (studies I and II)
CFU assay was used to identify primitive hematopoietic cells from 
CD133+, CD34+ CD133-, CD34- and mononuclear cells. A similar number 
of total CFUs were formed by CD133+ and CD34+ cells. CD133+ cells 
formed almost only multipotent granulocyte-erythroid-macrophage-
megakaryocyte (38%) and granulocyte-macrophage colonies (58%). 
Burst-forming colonies represented 4.2% of the progeny in CD133+ 
cells, whereas no erythroid colonies were observed. A vast majority 
of CD34+ cell progeny was also multipotential, 33% granulocyte-
erythroid-macrophage-megakaryocyte colonies and 58% granulocyte-
macrophage colonies. A little more of both the burst-forming (7.2%) and 
unipotent erythroid colonies (1.4%) were formed by CD34+ cells (Figure 
8). Combining the CFU assay and gene expression profi ling results it 
seems likely that CD133+ cells are more primitive in their nature when 
compared to CD34+ cells.
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Reanalysis of the original gene expression data 
focuses on the similarities between CD133+ and 
CD34+ cells
Due to the fast development of gene expression analysis and data 
normalization methods, the original data from microarray analysis 
(study I and II) were reanalyzed using a more modern method. In the 
reanalysis, the top 500 genes with differential expression in CD133+/
CD133- or CD34+/CD34- cells were chosen. After discharging putative 
false positive results, based on the q-value, 492 genes in the CD133+ 
gene expression profi le and 425 genes in the CD34+ gene expression 
profi le were considered valid (Figure 9). Of these, CD133+/CD133- and 
CD34+/CD34- cells had 283 differentially expressed genes in common. In 
comparison to CD133- and CD34- data, 118 genes were overexpressed 
and 165 genes were underexpressed in CD133+ and CD34+ cells. 
Reanalysis of the microarray data verifi ed the overexpression of 67 genes 
in CD133+ and CD34+ cells when compared to CD133- and CD34- cells. 
These include KIT, FLT3, MEIS1, HOX9A, GATA2 and SOCS2 genes with 
a signifi cant role in HSC regulation. Similarly, 73 genes downregulated 
in CD133+ and CD34+ cells, when compared to CD133- and CD34- cells, 
were the same between the original and reanalyzed data. No genes 
that were defi ned as overexpressed in CD133+ and CD34+ cells by the 
original data analysis were shown to be underexpressed after reanalysis, 
or vice versa. However, the reanalysis of the data identifi ed 51 new 
genes with a higher expression level in CD133+ and CD34+ cells than in 
Figure 8. Clonogenic progenitor capacity of CD34+ and CD133+ cells by CFU as-
say. Abbreviations: BFU, burst-forming erythroid; CFU, colony-forming unit; GEMM, 
granulocyte-erythroid-macrophage-megakaryocyte; GM, granulogyce-macrophage.
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CD133- and CD34- cells (data not shown). Moreover, 92 new genes were 
downregulated in CD133+ and CD34+ cells when compared to CD133- 
and CD34- cells. The role of these novel genes in the regulation of HSCs 
requires further investigation.
The association with a biological process was defi ned for the set of 
differentially expressed genes in the original data and the reanalyzed 
data. Only the genes similarly expressed in CD133+ and CD34+ cells were 
considered. Annotation was performed anew to both data sets (Figure 
10). In both cases, the biological processes representative of CD133+ 
and CD34+ cells were clearly different from their negative counterparts. 
The associated biological processes enriched in CD133+ and CD34+ cells 
have been shown to be characteristics to HSC populations106,109,199. Many 
of the related biological processes were the same between the original 
data and the reanalyzed data, especially in the processes that represent 
CD133- and CD34- cells.
The causes for genes with higher expression level in CD133+ and CD34+ 
cells than in CD133- and CD34- cells related to catalytic activity (38 
genes), cytokine activity (5 genes) and endopeptidase/protease inhibitor 
activity (4 genes). Cytokine activity-associated genes SOCS2, TNFSF4, 
TRIP6, PXDN and IPO11 were the same as identifi ed in the original 
data (studies I and II). The 4 protease inhibitor genes were SERPING1, 
SERPINE2, SPINK2 and TFPI. Similarly to other protease inhibitors200,201, 
Figure 9. Schematic representation of the number of differentially expressed 
transcripts in CB CD133+ and CD34+ cells (when compared to CD133- and CD34- cells) 
and their intersections. A) In the original data, differentially expressed transcripts 
between CD133+/CD133- and CD34+/CD34- samples represented at least a three-
fold change in all sample pairs (studies I and II). B) Reanalysis results represented 
the most differentially expressed genes between CD133+/CD133- and CD34+/CD34- 
samples based on the mean gene expression level of the replicates. No fold-change 
cutoff value was used.
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Figure 10. Biological processes represented by differentially expressed genes in 
CD133+ and CD34+ cells when compared to CD133- and CD34- cells. A) Original data 
(study II) and B) reanalyzed data.
these genes may have a role in the modulation of cytokine expression. 
Their overexpression in HSCs has been previously shown112,115,188,193. 
Forty-nine of the genes overexpressed in CD133+ and CD34+ cells were 
associated with intracellular compartments, especially to cytoplasm (25 
genes) (Table 4).
The genes downregulated in CD133+ and CD34+ cells when compared 
to CD133- and CD34- cells were associated with cell communication (32 
genes), response to other organism (17 genes), apoptosis (16 genes) 
and cell activation (7 genes). Moreover, the encoded protein products 
were associated with protein binding (42 genes) and receptor activity 
(20 genes). The most strikingly emphasized cellular compartment for 
the encoded gene products was cell membrane (55 genes). CD133- and 
CD34- cell populations include lymphocytes, mononuclear phagocytes, 
dendritic cells and granulocytes that act in the immune system. It is 
crucial for these cells to have active signaling and communication with 
both other cells and the matrix. The immune response is dependent on 
detected changes in the environment and the activation of the cell is 
initiated by extrinsic factors.
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Table 4. The most common cellular compartments for products encoded 
by expressed genes in CD133+ and CD34+ cells.
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The main functional categories related to the CD133+ and CD34+ gene 
expression profi les were the same in the original data and the reanalyzed 
data using the most recent annotation. There are several reasons to 
explain the differences between the original data and the reanalyzed data. 
These are: the difference between the redesigned probe sets and original 
Affymetrix probe sets, different preanalysis and normalization of  the 
data, and the criteria of the differentially expressed genes. Redesigned 
probe sets or sequence matched probes have shown a 30-50% discrep-
ancy of results in differential gene expression analysis when compared 
to analysis using the original Affymetrix probe sets181,202. It is important 
to notice that the differences between the original and reanalyzed data 
sets of differentially expressed genes in CD133+/CD133- and CD34+/
CD34- cells are not necessarily faulty results. Well-characterized genes 
expressed in CD133+/CD34+ cells are not all among the list of the most 
highly expressed genes in the reanalysis due to the selection criteria 
that was used. Thus, the differential gene expression that was shown 
in the original data, but not in reanalyzed data, is still in the main part 
usable. However, redesigned probes have the improved capacity to de-
tect the expressed genes. Thus, the reanalysis of the gene expression 
data may help in identifi cation of new genes and provide novel data for 
further studies.
CD133+ and CD34+ cells have divergent roles in 
hematopoietic regeneration (studies I and II)
The divergent gene expression between CD133+ and CD34+ cells was 
revealed by direct pairwise analysis. The represented analysis was 
specially focused on genes associated with hematopoiesis, cell cycle and 
cell adhesion. CD133+ cells had a higher expression level of CD133, CD34, 
CD135 (FLT3) and CD117 (KIT) genes. The higher expression of CD34 in 
the CD133+ cell population may be explained by the higher abundance 
of CD34 on the cell surface of CD133+ cells. Nearly all CD133+ cells 
are CD34-positive, whereas the CD34+ cell population includes lineage 
committed progenitors that carry a lower number of CD34 molecules on 
their cell surface. 
The hematopoietic lineage-specifi c markers were downregulated in 
CD133+ and CD34+ cells when compared to their negative counterparts. 
However, there was a difference in the level of underexpression between 
CD133+ and CD34+ cells (Table 5). CD133+ cells expressed IL3R (CD123), 
a marker typical for common myeloid progenitors, pronormoblasts and 
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megakaryoblasts. The other genes encoding megakaryoblast markers, 
such as IL-11R or CD126, were not expressed in CD133+ cells. On the 
other hand, one or more of the CD34+ sample replicates expressed 
several genes related to hematopoietic diffentiation. The complete list 
of genes related to hematopoiesis is shown in Table 5.
The lineage differentiation marker expression may be connected to the 
cells in the CD133+ and CD34+ subpopulations. Hence, these results 
suggest that the CD34+ cell population contains a higher proportion of 
pro T cells, other differentiating T cells, promonoblasts, monoblasts and 
megakaryocytes than the CD133+ cell population (Figure 1). On the other 
hand, it has been suggested that HSCs express lineage differentiation 
marker genes at a low level to enable the fast differentiation of HSCs 
when a differentiated cell type is needed in the blood system. It may 
also be that CD34+ cell population consists of a higher number of short-
term HSCs with better readiness to form all types of blood cells.
CD34+ cells expressed a wider variety of genes encoding cell adhesion 
molecules, such as selectin E and selectin P. Selectins are important for cell 
traffi cking. CD34+ cells may thus have greater capacity to be mobilized. 
However, the engraftment potential of CB HSCs has been delayed when 
compared to HSCs from other sources203. The presence of very late antigen 
4 has been proven crucial for the homing of HSCs204. The expression of 
gene coding for very late antigen 4 was higher in CD133+ cells.
The gene expression profi le of CD133+ cells revealed the expression of 
many genes related to the cell cycle (study I). CD133+ cells expressed 
20 cell cycle genes on a higher level than CD34+ cells. These products of 
the cell cycle genes have inhibitor as well as promoter effects. The results 
suggest that both quiescent cells and actively cycling cells are found in 
the CD133+ cell population. Long-term HSCs are mostly considered to be 
noncycling, but that is not as critical a parameter in CB HSCs91. Hence, 
CB HSC in an active cell cycle state can have self-renewing capacity. 
CD133+ and CD34+ cells had a high number of commonly expressed 
genes typical of HSCs. They also had many overlapping biological 
processes. Both CD133+ and CD34+ cells have been successfully used in 
the reconstruction of the blood system in irradiated patients’ marrow. 
Thus both cell populations contain cells with long-term repopulation and 
short-term repopulation potential. The direct comparison of CD133+ and 
CD34+ cells revealed very delicate differences between the cell types. 
Previous studies have shown that differences in the gene expression 
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profi le refl ect true changes between closely related cell populations205,206. 
Thus, the differences demonstrated in expression profi les of CD133+ and 
CD34+ cells suggest functional divergences between the cell types.
The gene expression profi les indicate that faster repopulation of the 
recipient could be obtained after CD34+ cell transplantation. Due to the 
more primitive nature of CD133+ cells, selected CD133+ cell population 
may not include enough cells readily available for development of all 
blood cell types or they may have poorer capacity to travel into the BM, 
Table 5. Differential expression of hematopoietic cell marker genes in 
CD133+ and CD34+ cells.
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or both. CD133+ cells, as a more primitive source of HSCs, could be 
better suited for HSC expansion and gene therapy. Due to the limited 
number of transplantations performed using selected CD133+ and 
CD34+ cells, it is not possible to say whether there is a difference in 
the repopulation after transplantation. It should be kept in mind that 
despite the divergent biological capacities, binding of an antibody to the 
CD133 or CD34 molecules may infl uence cell function.
N-glycosylation-related gene expression is similar in 
CD133+ and CD34+ cells and correlates with the N-
glycome profi le (study III)
CD133+ and CD34+ cells had characteristic N-glycosylation-related gene 
expression when compared to CD133-/CD34- cells (study III). Moreover, 
mass spectrometric analysis of CD133+ and CD133- cells, combined with 
results from NMR and exoglycosidase digestion, revealed differences in 
the glycosylation of these cells. CD133+ cells contained signifi cantly more 
fully processed, especially biantennary type N-glycans than CD133- cells 
(Figure 11). Yet, fully processed multiantennary N-glycans were fewer 
in CD133+ cells than in CD133- cells. The most frequent glycosylation 
of CD133+ cells was unprocessed, high-mannose type N-glycans. High 
mannose type N-glycans were more abundant in CD133+ cells than in 
CD133- cells.
Enrichment of high mannose type N-glycans in CD133+ cells was evident 
in the comparison of CD133+ cells to CD8+ cells which represent a 
mature leukocyte population (data not shown). However, more analyses 
are needed to confi rm that the differences in the relative abundance of 
neutral N-glycans are due to tissue-specifi c glycosylation changes.
Characteristic mannosylation pattern of CD133+ and 
CD34+ cells (study III)
The differential expression of one mannosidase and three 
glycosyltransferase encoding genes were related to the changes observed 
in the CD133+ and CD133- cell glycome. The differential gene expression 
was observed in both CD133+ and CD34+ cells as compared to their 
negative counterparts. CD133+ and CD34+ cells, but not CD133- and 
CD34- cells, lacked the expression of MAN1C1 encoding one of the key 
α1,2-mannosidases participating in N-glycan maturation. No difference 
was seen in the expression of other α1,2-mannosidase encoding genes 
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MAN1A1, MAN1A2 and MAN1B1, yet their expression was detected in 
CD133+ and CD34+ cells as well as CD133- and CD34- cells.
MAN1 enzymes remove α1,2-mannosidases from different positions in 
N-glycans, and their functions are highly overlapping (Figure 6). MAN1A, 
MAN1B and MAN1C are located in different genes on chromosomes 6 
and 1, and they have independent regulatory pathways. The unique 
specifi city of MAN1C1 encoded α1,2mannosidase 1C is that it prefers 
the removal of terminal α1,2-linked mannose on the α1,3 branch in 
Man9GlcNAc2 and Man8GlcNAc2 isomer B
207. The α1,2-mannosidases 1A 
and 1B remove terminal α1,2-linked mannose from the α1,6 branch 
from Man8GlcNAc2 isomer B before the α1,3 branch is demannosylated. 
Hence, the absence of MAN1C1 expression in CD133+ and CD34+ cells 
may affect the enrichment of high mannose N-glycans. It is likely that 
most of the high mannose N-glycans seen in the CD133+ and CD133- 
cell glycan profi le were intracellular. N-glycan profi les include all N-
glycans, not only those on the cell surface. However, labeling with 
mannose binding lectins Pisum sativum agglutinin and Hippeastrum 
hybrid agglutinin confi rmed the presence of mannose-rich N-glycans on 
the cell surface.
High mannose N-glycans promote proper protein folding208. The high 
mannose N-glycans transported to the cell surface are known to be 
demannosylated. A half-life of 6.7 hours for cell surface high mannose 
Figure 11. Schematic representation of the differences in CD133+ and CD133- cell N-
glycan profi les. In CD133+ cells, high mannose N-glycans and biantennary complex type 
N-glycans were the most enriched N-glycan structures. In contrast, the proportion of low 
mannose type N-glycans and multiantennary structures greater than biantennary com-
plex N-glycans was increased in CD133- cells. Monosaccharide symbols: =    N-acetyl-D-
glucosamine;    = D-mannose. Glycosidic linkages are indicated by lines connecting the 
monosaccharides.
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N-glycans has been observed in the hepatic cell line209. On the other 
hand, 4TO7 tumor cells are capable of spreading to the lungs and they 
have been shown to have more high mannose and N-glycans on their cell 
surface than nonmetastatic tumor cells210. Further, it has been shown 
that sialic acids have no effect on the migration and invasion properties 
of 4TO7 cells. Thus, high mannose N-glycans may have yet unknown 
functions. 
The 5% increase of high mannose type N-glycans demonstrated in 
CD133+ cells when compared to CD133- cells may correspond to a 
variety of glycoproteins. There may be a greater number of recently 
transported proteins on the surface of CD133+ cells. Hence, there may 
simply be more time for trimming mannose residues to form the low 
mannose type N-glycans more abundant in CD133- cells. If there is a 
greater proportion of mannose-rich glycans on the surface of CD133+ 
cells, it could be due to the lower number of mannose trimming enzymes 
in these cells. The unique mannosylation of CD133+ cells may be useful 
for classifi cation of a primitive cell type. The lack of MAN1C1 expression 
may function as a marker for HSCs. 
Differential expression of N-acetylglucosaminyl-
transferase genes and the enrichment of biantennary 
complex type N-glycans in CD133+ cells (study III)
Differential expression of two genes encoding N-glycan backbone 
branching N-acetylglucosaminyltransferase enzymes was demonstrated 
between CD133+/CD133- and CD34+/CD34- cells. MGAT2 was overex-
pressed 1.9-fold in CD133+ cells when compared to CD133- cells. MGAT2 
overexpression was 1.7-fold in CD34+ cells when compared to CD34- 
cells. MGAT4A was underexpressed 2.8-fold in CD133+ cells and 2.0-
fold in CD34+ cells when compared to their negative counterparts. The 
increase in the amount of biantennary complex type N-glycans demon-
strated in CD133+ cells correlated with the higher expression of MGAT2. 
Furthermore, a lower number of triantennary and other multiantennary 
N-glycans were seen in CD133+ cells. MGAT4 gene encoding N-acetyl-
glucosaminyltransferase 4 participates in the biosynthesis of trianten-
nary and other multiantennary complex type N-glycans. Thus, underex-
pression of MGAT4A may be related to the reduction of multiantennary 
N-glycans in CD133+ and CD34+ cells. Complex type N-glycans seem 
to be developmentally important as MGAT2-null mice suffer from he-
matological and osteogenic abnormalities and die soon after birth. This 
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indicates that complex type N-glycans could have a function in the in-
teraction between HSCs and BM osteoblasts. High binding of Phaseolus 
vulgaris-derived Phytohemagglutinin-L lectin, specifi c to large complex 
type N-glycans, demonstrated the presence of large complex type N-
glycans on leukocytes including the CD34+ cells.
Despite the differential expression of genes coding 
for β1,4-galactosyltransferases there are no 
differences in the β1,4-galactosylation of CD133+ 
and CD133- cells (study III)
Type 2 N-acetyllactosamine dominated as glycan backbone structure 
in CD133+ and CD133- cells. Mass spectrometric analysis results were 
verifi ed by binding of Ricinus communis agglutinin-1 lectin. Moreover, 
type 2 N-acetyllactosamine were β1,4-galactosylated as β1,3-linked 
galactose was not detected. Genes encoding β1,4-galactosyltransferases 
such as B4GALT1, B4GALT3 and B4GALT4 were expressed in CD133+, 
CD133-, CD34+ and CD34- cells. B4GALT3 was downregulated in CD133+ 
and CD34+ cells by 2.3- and 2.0-fold respectively, when compared to 
their negative counterparts. 
The differential expression of β1,4-galactosyltransferase encoding genes 
was not shown to have any effect on N-glycosylation. Yet, it may not be 
ruled out that the differential expression of β1,4-galactosyltransferase 
encoding genes still have a signifi cant function in the galactosylation of 
specifi c proteins not detected in glycan profi ling, or have an impact on the 
galactosylation of other glycan types such as O-glycans or glycolipids.
CD133+ and CD34+ cell specifi c biosynthesis of
N-glycan terminal epitopes (study III)
The complex type N-glycans, biantennary and larger, were very often 
α2,6-sialylated in CD133+ and CD133- cells. ST6Gal1 encoding α2,6-
sialyltransferase was similarly expressed in CD133+/CD133- cells, and 
CD34+/CD34- cells. Lectin Sambucus nigra agglutinin recognizing α2,6-
linked sialic acid bound to 98% of the leukocytes including CD34+ cells. 
Thus, α2,6-sialylation was a dominant terminal epitope on CD133+ and 
CD133- cells. Moreover, α2,3-sialylation had increased on CD133+ cells 
when compared to CD133- cells. The α2,3-sialidase digestion disclosed 
the presence of some solely α2,3-sialylated N-glycans in CD133+ cells. 
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The α2,3-sialidase treatment was not able to entirely desialylate N-
glycans in CD133- cells. CD133+ and CD34+ cells overexpressed the α2,3-
sialyltransferase encoded by ST3GAL6 when compared to their negative 
counterparts (CD133- and CD34- cells). ST3GAL6 expression was 3.9-fold 
higher in CD133+ cells than CD133- cells, and 1.6-fold higher in CD34+ 
cells than CD34- cells. Lectin Maackia amurensis agglutinin with α2,3-
linked sialic acid specifi city bound to 62% of the leukocytes and CD34+ 
cells demonstrating the presence of α2,3-sialyl-N-acetyllactosamine 
structures on the cell surface.
α2,3- and α2,6-sialyltransferases compete for the same N-glycan 
substrates. Lowered amount of α2,6-sialyltransferase and decreased 
α2,6-sialylation in murine T cells was suggested to be caused by 
substrate competition with α1,3-galactosyltransfase211. However, α1,3-
galactosyltransferase is not present in human cells and similar substrate 
competition is not relevant in humans. The lower relative abundance 
of α2,6-sialylation in CD133+ cells is likely to be caused by increased 
α2,3-sialylation. ST6Gal1 or ST3Gal6 have not been shown crucial for 
development. B cells express CD22 (Siglec2) that specifi cally binds to 
α2,6-linked sialic acid. However, Siclec2 functions only in activated B cells, 
while it is masked by the cell's own α2,6-sialylation in resting B cells212. B 
cells that have reduced sialylation have been shown more susceptible to 
apoptosis213. Similar masking by sialic acids could also exist in other cell 
types to prevent Fas receptor ligand driven apoptosis. HSCs upregulate Fas 
upon active cell cycle, but remain resistant to Fas-induced suppression214. 
Fas ligand coating of HSCs improves their engraftment capacity by two-
fold215. In addition, HSCs have shown to secrete Fas ligand which targets 
the marrow cells of the recipient in transplantation215.
Sialylation has been suggested to play a role in the initial attachment 
of HSCs to BM osteoblasts158. However, the participation of any single 
adhesion molecule in the homing of HSCs has not been unequivocally 
shown216. Glycosylation-based recognition may be involved in the initial 
steps of homing, but the binding of specifi c proteins are required for 
engraftment. The interaction may involve expression of stem cell factor 
and stromal cell-derived factor 1, activation of lymphocyte function-
associated antigen 1, very late antigen 4, very late antigen 5 and CD44, 
cytoskeleton rearrangements and secretion of membrane type 1–matrix 
metalloproteinases217. In the future, it would be interesting to fi nd out 
whether α2,3-sialylation is the only form of sialylation in certain proteins. 
It is also not yet known if solely α2,3-sialylated structures are typical 
of BM CD133+ cells as well. More studies are needed to reveal whether 
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the differential sialylation observed in CB CD133+ cells is benefi cial 
to cell function or if these cells would benefi t from a higher level of 
sialylation.
Only a small amount of CD34+ cells have been shown to bind to 
hyaluronan in BM. The α2,3-sialylation of N-glycans has been shown 
reduce the binding of CD44 molecule to hyaluronan in CHO cell line218. 
Enriched α2,3-sialylation may have a role in the mobilization of HSCs 
to the circulatory system. CD34+ cells carry a specifi c glycoform of 
CD44 molecule on their cell surface165. It has been shown to have over 
5-fold L-selectin binding when compared to P-selectin glycoprotein 
ligand 1168.
Selectin ligand sialyl-Lewisx is dependent on α2,3-sialylation and α1,3-
fucosylation219. In addition to common α1,6-fucosylation of N-glycan 
core structures, one or two more fucose residues were revealed in 
CD133+ and CD133- cell N-glycans by mass spectrometric analysis. The 
fucose was expected to be α1,2- or α1,3-linked to the N-glycans as no 
type 1 N-acetyllactosamine was found on CD133+ or CD133- cells. FUT1 
and FUT2 both encode α1,2-fucosyltransferase, but their expression 
was not reliably analyzed. FUT1 expression was not detected in CD133+/
CD34+ cells or their negative counterparts. For FUT2 there was no probe 
available on the array. Ulex europaeus agglutinin I lectin with specifi city 
towards α1,2-linked fucose residues labeled 53% of the leukocytes. 
Impaired α1,3-fucosylation and decreased α1,3-fucosyltransferase 
expression has been shown to be characteristic of CB CD34+ cells163,164. 
In order to defi ne α1,3-linked fucose on CD133+ or CD133- cell N-glycans, 
leukocytes were labeled with Lotus tetragonolobus agglutinin lectin. 
It bound to only 6% of leukocytes. Moreover only FUT4, but no FUT7 
expression was detected in CD133+, CD34+, CD133- and CD34- cells. 
FUT4 was expressed similarly in all cell types. FUT7 encodes the main 
α1,3-fucosyltransferase responsible for the synthesis of sialyl-Lewisx, 
but FUT4 protein product is also able to synthesize it. These results 
suggest that poor α1,3-fucosylation is typical for the CB leukocytes 
including CD34+ cells.
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CONCLUSIONS
The positive selection of HSCs has provided an attractive alternative 
to T cell depletion of transplantable cells. The selection of CD34+ cells 
can be used in this process. However, the selection of CD133+ cells has 
also shown to be promising in the enrichment of HSCs220-222. Although, 
CD133+ and CD34+ cells are highly similar cell populations there may be 
differences in their genetic regulation. In previous studies, HSCs from BM, 
PB and CB have shown differential gene expression related to divergent 
biological properties operative in HSCs10,155,223. Increased knowledge of 
HSC biology is crucial to improve stem cell-based therapies.
The present studies characterize human CB-derived CD133+ and CD34+ 
cells on a genomic level and provide gene expression profi les of CD133+ 
and CD34+ cells when compared to CD133-and CD34- cells, respectively. 
The integrated CD133+/CD34+ cell gene expression profi les reveal novel 
genes to specify HSCs. Moreover, the transcripts that are expressed 
differentially between CD133+ and CD34+ cells are associated with cell 
cycle, cell adhesion and differentiation. This fi nding suggests that the 
divergent gene expression patterns may be adjusting CD133+ and CD34+ 
cells in different ways in order to encompass hematopoiesis. CD133+ 
cells seem to be more primitive in their nature and possibly have a wider 
differentiation potential than CD34+ cells. CD133+/CD34+ cells express 
numerous transcripts coding for putative transmembrane proteins that 
may serve as markers for HSCs. However, during this study, specifi c 
markers to identify HSCs could not be found on the cell surface of 
CD133+ or CD34+ cells.
These studies also demonstrate N-glycan structure profi le typical for 
CD133+ cells. CD133+ cells have enriched amount of high mannose type 
and biantennary complex type N-glycans when compared to CD133- cells. 
CD133+ cells also have solely α2,3-sialylated N-glycans. Comparison 
of N-glycan structure and gene expression profi les identify key genes 
regulating the CD133+ cell-specifi c N-glycan synthesis. The expression 
pattern of genes encoding glycosyltransferases and glucosidases is 
similar in CD133+ and CD34+ cells, suggesting a similar N-glycosylation 
in CD133+ and CD34+ cells. Furthermore, the specifi c binding properties 
of various lectins are utilized to reveal the glycan determinants on the 
cell surface.
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Further studies to identify proteins that carry the specifi c N-glycan 
structures in CD133+ cells could prove useful in the recognition and 
isolation of HSCs. Moreover, the role of glycans and glycan binding 
proteins in the communication between HSCs and their environment 
should be elucidated. The modifi cation of HSC glycosylation could 
increase HSC homing and engraftment or target them to specifi c tissues. 
In conclusion, these results provide new knowledge of CD133+ and CD34+ 
cells that could help to design cells with enhanced biological properties 
and to further the use of HSCs in novel therapeutic applications.
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